Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting

HUNTINGTON BEACH, California and AMSTERDAM, June 4, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test. FDA clearance requires clinical and analytical validation and full transparency to ensure patient safety issues are addressed. The company anticipates launching its prognostic colon cancer test ColoPrint in late 2010.

The study results underpin the broad predictive and prognostic power of MammaPrint and highlight prospective and independently validated data on ColoPrint. Visitors can meet the Agendia team in booth #18018 and study results will be discussed at the following sessions:

    Breast Cancer

    Date: Saturday, June 5, 2010


    POSTER PRESENTATION - Abstract #10615

    Substratification of 70-gene high-risk breast cancers with a
    validated 80-gene molecular subtyping profile

    F. de Snoo, B. Chan, P. Roepman, R. A. Bender, A. Glas

    Time: 8:00 AM - 12:00 PM

    Location: S Hall A2

    Date: Saturday, June 5, 2010


    POSTER PRESENTATION - Abstract # 540

    Gene signatures as predictors of response to neoadjuvant
    chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC),
    or AC and nab-paclitaxel (nab-P) and carboplatin plus or minus
    trastuzumab in patients (pts) with stage II-III and inflammatory breast
    cancer (IBC)

    G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L.
    Kruper, J. Yim, Y. Yen, F. de Snoo, R. A. Bender

    Time: 2:00 PM - 6:00 PM

    Location: S Hall A2

    Date: Saturday, June 5, 2010


    POSTER PRESENTATION - Abstract # 561

    Evaluation of the 70-gene prognosis MammaPrint signature for
    the prediction of prognosis of breast cancer independently from
    histologic grade

    M. Knauer, E. J. Rutgers, S. Mook, J. Wesseling, L. J. van 't
    Veer

    Time: 2:00 PM - 6:00 PM

    Location: S Hall A2

    Date: Monday, June 7, 2010


    POSTER DISCUSSION - Abstract # 1520

    Effect of screening on the detection of good and poor
    prognosis breast cancers

    Y. Shieh, L. Esserman, E. J. Rutgers, M. Knauer, V. Retel, S.
    Mook, A. Glas, S. C. Linn, F. E. van Leeuwen, L. van't Veer

    Time: 2:00 PM - 6:00 PM / 5:00 PM - 6:00 PM (discussion in
    E451b)

    Location: E450b


    Colon Cancer

    Date: Monday, June 7, 2010


    POSTER PRESENTATION - Abstract # TPS199

    The PARSC trial, a prospective study for the assessment of
    recurrence risk in stage II colon cancer (CC) patients using ColoPrint

    R. Salazar, J. Marshall, L. Stork-Sloots, I. Simon, M. Lutke
    Holzik, J. Tabernero, J. J. Van Der Hoeven, F. Bibeau, R. Rosenberg

    Time: 8:00 AM - 12:00 PM

    Location: S Hall A2

    Date: Tuesday, June 8, 2010


    POSTER DISCUSSION - Abstract # 3513

    Independent validation of a prognostic genomic profile (ColoPrint) for
    stage II colon cancer (CC) patients

    R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, M. Snel, I.
    Simon, K. Janssen, H. Friess

    Time: 11:00 AM - 12:00 PM

    Location: S 406 (Vista Room)

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis risk - patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CAP-accredited and CLIA compliant service laboratories.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

SOURCE Agendia B.V.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.